-
Beijing-Based Holox Secures Tens of Millions in Series A+ Financing for Healthcare Software
•
Holox, a Beijing-based developer of healthcare management software, has reportedly secured tens of millions of renminbi in a Series A+ financing round. The funds raised will be directed towards the research and development of new products and the globalization of the company’s operations. Company Background and Pharmaceutical Safety ServicesFounded in…
-
Shanghai Kingstar Winning Secures $43.39 Million in Series C Financing for Digital Healthcare Solutions
•
Shanghai Kingstar Winning Software Science and Technology Co., Ltd, a leading provider of digitalization risk control solutions for medical and commercial insurance, has reportedly raised RMB 300 million (USD 43.39 million) in a Series C financing round. The round was led by China Taiping Insurance Group Company’s healthcare funds, with…
-
Luzhu Biotech Prepares for HKD 433 Million IPO with Focus on Vaccines and Biologics
•
Beijing Luzhu Biotechnology Co., Ltd, a leading manufacturer of human vaccines and therapeutic biologics, is preparing for an initial public offering (IPO) of 10,386,000 shares at HKD 41.65 (USD 5.31) per share, which is expected to raise a total of HKD 433 million (USD 55.1 million). Company Background and Product…
-
Gan & Lee Pharmaceuticals Receives Marketing Approval for Insulin Glargine in Bolivia
•
Gan & Lee Pharmaceuticals (SHA: 603087), a China-based pharmaceutical company, has announced that it has received marketing approval from Bolivia’s State Agency of Drugs and Health Technologies (AGEMED) for its insulin glargine product, which comes in a pre-filled format. Insulin Glargine: A Long-Acting Insulin AnalogueInsulin glargine is a long-acting insulin…
-
Rainmed Medical’s caIMR System Receives NMPA Approval for Coronary Artery Function Measurement
•
China-based Rainmed Medical Limited has announced that it has received market approval from the National Medical Products Administration (NMPA) for its innovative coronary artery function measurement system, the caIMR system. Microcirculatory Resistance Index (IMR) and Its Clinical SignificanceThe microcirculatory resistance index (IMR) is a quantitative method used to evaluate the…
-
WuXi AppTec Reports 5.77% YOY Revenue Growth and 31.97% Increase in Net Profits for 2023Q1
•
WuXi AppTec Co., Ltd (SHA: 603259, HKG: 2359) has released its financial report for the first quarter of 2023, recording RMB 8.964 billion (USD 1.29 billion) in revenues, marking a 5.77% year-on-year (YOY) increase, and net profits of RMB 2.168 billion (USD 313.6 million), up 31.97% YOY. Client Expansion and…
-
SMPA Suspends Procurement of Levornidazole by Warrant Pharmaceutical Over IP Concerns
•
Shanghai’s Sunshine Medical Procurement All-in-One (SMPA) has released a notification to suspend the procurement status of two levornidazole specifications manufactured by Hunan Warrant Pharmaceutical Co., Ltd (SHA: 688799), citing the need for intellectual property (IP) protection. Additionally, Anhui province has also paused the procurement of two levornidazole specifications made by…
-
Tot Biopharmaceutical Partners with Suzhou Smart Nuclide on Radioactive Drug Development
•
China-based Tot Biopharmaceutical International Co., Ltd (HKG: 1875) has announced a strategic partnership with Suzhou Smart Nuclide Pharmaceutical Technology Company, a move focused on the development of radioactive drugs based on conjugate technology. Complementary Expertise in RadiopharmaceuticalsUnder the terms of the partnership, Tot Bio will offer a comprehensive antibody conjugate…
-
GSK’s Cervarix Receives Approval for Two-Dose Schedule in China for Ages 9 to 14
•
The UK-based pharmaceutical giant GSK plc (NYSE: GSK) has announced the official market launch of a two-dose schedule for its bivalent recombinant human papillomavirus (HPV) vaccine, Cervarix (types 16 and 18), targeting girls aged 9 to 14 in China. Cervarix’s Approval History and Expansion in ChinaCervarix was first approved in…
-
Everest Medicines’ Nefecon for IgAN Approved for Clinical Use in Hainan
•
China-based Everest Medicines (HKG: 1952) has announced that Nefecon (delayed-release budesonide), the first-in-disease treatment for primary immunoglobulin A nephropathy (IgAN), has been approved by the Hainan Medical Products Administration for clinical use in Shanghai Ruijin Hospital’s Hainan subsidiary. This marks the beginning of a new treatment era for IgA nephropathy…
-
Grand Pharmaceutical Group to Acquire Majority Stake in BlackSwan Vascular Inc. for $37.5 Million
•
Grand Pharmaceutical Group Limited (HKG: 0512), a China-based pharmaceutical company, has announced plans to acquire an 87.5% stake in US-based liquid embolic agent specialist BlackSwan Vascular Inc., for USD 37.5 million. This strategic move signifies Grand Pharma’s commitment to expanding its global presence in the medical device industry. BlackSwan Vascular…
-
Zelgen Biopharmaceuticals’ ZG2001 Receives US FDA Clinical Trial Approval for Pan-KRAS Inhibitor
•
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that it has received clinical trial approval from the US Food and Drug Administration (FDA) for its Category 1 product candidate, ZG2001. ZG2001 is an in-house discovered oral pan-KRAS mutation inhibitor under development for the treatment of KRAS mutant tumors. Prevalence…
-
Sichuan Biokin Pharmaceutical Gets NMPA Approval for Two Clinical Studies on Cancer Therapies
•
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a China-based pharmaceutical company, has announced receiving approval from the National Medical Products Administration (NMPA) to conduct two clinical studies. One study will investigate the combination of its drug candidate BL-B01D1 with osimertinib (Tagrisso) for the treatment of locally advanced or metastatic non-small…
-
YiChang HEC ChangJiang Pharmaceutical Reports 309.83% YOY Revenue Growth in 2022 Financials
•
YiChang HEC ChangJiang Pharmaceutical Co., Ltd (HKG: 1558), a China-based pharmaceutical company, has released its financial report for 2022, recording revenues of RMB 3.745 billion (USD 582.8 million), marking a substantial increase of 309.83% year-on-year (YOY). The company transitioned from a previous year loss to achieve net profits of RMB…
-
LianBio Appoints Pascal Qian as COO in Anticipation of Mavacamten Market Launch
•
China-based biotech firm LianBio (OTCMKTS: LIANY) has announced the promotion of its current China General Manager (GM), Pascal Qian, to the position of Chief Commercial Officer (COO). This strategic move comes as LianBio prepares for the potential market launch of mavacamten, a first-in-class molecule for the treatment of obstructive hypertrophic…
-
Suzhou Basecare Medical and Qitan Tech Partner to Advance Nanopore Sequencing in PGT
•
Suzhou Basecare Medical Co., Ltd (HKG: 2170), a China-based in vitro fertilization (IVF) specialist, has announced a strategic partnership with Qitan Tech, a Chengdu-based nanopore gene sequencer manufacturer. The collaboration aims to drive technology development, regulatory filings, localization, and industrialization of nanopore gene sequencers in the preimplantation genetic testing (PGT)…
-
Jiangsu Hengrui Pharmaceuticals’ Pyrotinib Gains NMPA Approval for HER2+ Breast Cancer Treatment
•
Jiangsu Hengrui Pharmaceuticals (SHA: 600276), a leading China-based pharmaceutical company, has announced receiving another indication approval from the National Medical Products Administration (NMPA) for its small-molecule HER2 inhibitor, pyrotinib. The drug is now approved for use in combination with Herceptin (trastuzumab) plus chemotherapy to treat recurrent or metastatic breast cancer…
-
Evopoint Biosciences Gets CDE Approval for Phase I/II Study of XNW27011 ADC
•
Suzhou Evopoint Biosciences Co., Ltd., a China-based pharmaceutical company, has announced receiving approval from the Center for Drug Evaluation (CDE) to conduct a Phase I/II clinical study for its antibody-drug conjugate (ADC), XNW27011. The study will focus on locally advanced unresectable or metastatic malignant solid tumors expressing Claudin 18.2 (CLDN18.2).…
-
ChengDu ShengNuo Biotech Secures NMPA Approval for Generic Firazyr Equivalent
•
ChengDu ShengNuo Biotech Co., Ltd (SHA: 688117), a China-based polypeptide specialist, has announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its generic version of Shire’s Firazyr (icatibant). This marks a significant milestone as the company becomes the first manufacturer to file for Drug…
-
CanSino Biotechnology Leads RMB 500 Million Private Equity Fund for Vaccine Investments
•
China-based vaccines specialist CanSino Biotechnology Inc., (HKG: 6185) has announced plans to invest RMB 140 million (USD 20.3 million) in the establishment of a private equity fund with a total value of RMB 500 million (USD 72.5 million). The fund will focus on investments in vaccine companies, highlighting CanSino’s commitment…
